Armata Shares Surge As FDA Gives Green Signal To Its Second Program To Enter Human Trial(s)

The FDA has cleared Armata Pharmaceuticals Inc's ARMP Investigational New Drug (IND) for Phase 1b/2a study of AP-SA02 in Staphylococcus aureus bacteremia.
Armata expects to begin the study by the end of 2021.
The trial, dubbed diSArm, will be Armata's second program to enter clinical development and funded in part by a $15 million award from the U.S. DoD with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.
The diSArm study will assess the safety, tolerability, and efficacy of intravenous AP-SA02 as an adjunct to best available antibiotic therapy compared to best available antibiotic therapy alone.
Armata has also achieved a development milestone under the Therapeutics Development Award from the CF Foundation to support its Phase 1b/2a SWARM-P.a.
The trial is evaluating its lead therapeutic candidate, AP-PA02, for Pseudomonas aeruginosa upper airway infections in cystic fibrosis patients.
The latest milestone achievement triggers a $2 million payment bringing the total to $3.75 million achieved under the Award.
Related content: Benzinga's Full FDA Calendar.
Price Action: ARMP shares are up 26.40% at $4.74 during the market session on the last check Thursday.